Cedars-Sinai study finds two key proteins could help protect the liver from cancerous cells

AI-based blood test outperforms ultrasound in early liver cancer detection

Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has released results from its latest clinical trial demonstrating the superior performance of their HelioLiver Dx test compared to ultrasound.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Liver surgery to remove cancer can now be a safe outpatient procedure

Robotic liver surgery can be a safe outpatient procedure, according to a study published in the Journal of the American College of Surgeons. In fact, 8% of the patients sampled in the analysis were discharged to go home on the same day.

June 14, 2024

Vol.50 No.24

In Brief

Indrin Chetty named vice chair of research, director of medical physics division in Department of Radiation Oncology at Cedars-Sinai

Indrin Chetty was selected as the new vice chair of research and director of the medical physics division in the Department of Radiation Oncology at Cedars-Sinai Cancer.

May 10, 2024

Vol.50 No.19

In Brief

Mauricio Garcia named Jerome S. Levy, MD, Chair in Gastroenterology and Hepatology at UAMS

The University of Arkansas for Medical Sciences College of Medicine invested Mauricio S. Garcia in the Jerome S. Levy, MD, Chair in Gastroenterology and Hepatology during a May 1 ceremony.

May 10, 2024

Vol.50 No.19

Clinical Roundup

Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization

Positive results from the EMERALD-1 phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival compared to TACE alone in patients with hepatocellular carcinoma eligible for embolization.

March 29, 2024

Vol.50 No.13

In Brief

Leo Mascarenhas named director of Pediatric Hematology & Oncology at Cedars-Sinai Guerin Children’s

Leo Mascarenhas was named director of Pediatric Hematology & Oncology at Cedars-Sinai Guerin Children’s and medical director of the Sarcoma Program at Cedars-Sinai Cancer Center.

March 15, 2024

Vol.50 No.11

Cedars-Sinai study finds two key proteins could help protect the liver from cancerous cells

YOU MAY BE INTERESTED IN

AI-based blood test outperforms ultrasound in early liver cancer detection

Liver surgery to remove cancer can now be a safe outpatient procedure

Indrin Chetty named vice chair of research, director of medical physics division in Department of Radiation Oncology at Cedars-Sinai

Mauricio Garcia named Jerome S. Levy, MD, Chair in Gastroenterology and Hepatology at UAMS

Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization

Leo Mascarenhas named director of Pediatric Hematology & Oncology at Cedars-Sinai Guerin Children’s

Renew today!

Subscriber content

Login